BRIEF published on 02/10/2026 at 07:35, 2 months 27 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
BRIEF published on 02/10/2026 at 07:35, 2 months 27 days ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
BRIEF published on 02/10/2026 at 07:35, 2 months 27 days ago Premiers Pas de l'Étude Clinique REVISE sur GS010/LUMEVOQ® Thérapie Génique Étude Clinique GenSight Biologics LUMEVOQ Neuropathie Optique
PRESS RELEASE published on 02/10/2026 at 07:30, 2 months 27 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
PRESS RELEASE published on 02/10/2026 at 07:30, 2 months 27 days ago Informations privilégiées / Autres communiqués L'Hôpital national des 15-20 et GenSight Biologics traitent le premier patient dans l'étude REVISE de GS010/LUMEVOQ contre la neuropathie optique héréditaire de Leber en France GenSight Biologics Neuropathie Optique GS010/LUMEVOQ Hôpital Des 15-20 Étude REVISE
BRIEF published on 01/29/2026 at 00:26, 3 months 11 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
BRIEF published on 01/29/2026 at 00:26, 3 months 11 days ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
PRESS RELEASE published on 01/29/2026 at 00:21, 3 months 11 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 4 months 11 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
BRIEF published on 12/29/2025 at 08:05, 4 months 11 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
Published on 05/09/2026 at 01:30, 11 hours 32 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 13 hours 2 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 16 hours 24 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 17 hours 49 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 18 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 17 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 17 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 17 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 17 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 18 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
